SPOTLIGHT -
Dr. Crew on Treatment in Favorable-Risk HER2+ Breast Cancer
Katherine Crew, MD, MS, discusses treatment for patients with favorable-risk early-stage HER2-positive breast cancer.
Read More
Dr. Crew on New Research in Advanced HER2+ Breast Cancer
Katherine Crew, MD, MS, discusses new research in the advanced HER2-positive breast cancer landscape.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
